Asthma disparities has been a priority topic for PCORI for some time. To date, the Addressing Disparities program has funded 8 projects totaling $23 million on multi-level/multi-component interventions to improve asthma outcomes and reduce disparities in African-American/Hispanic/Latino populations. We are now considering a targeted therapeutic research topic to complement our portfolio. Informed by the AHRQ review on allergen-specific immunotherapy and recent conversations with stakeholders, we are considering funding one or more trials on the comparative effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic asthma, with a specific interest in how this treatment could reduce disparities in asthma outcomes.
We convened a workgroup of experts, patients, and stakeholders to answer some very specific questions about sponsoring this type of trial.
In-person attendance was by invitation only, but the public was welcome to listen in via teleconference and webinar.